Literature DB >> 17035666

Salvinorin A: from natural product to human therapeutics.

Timothy A Vortherms1, Bryan L Roth.   

Abstract

The hallucinogenic plant Salvia divinorum (i.e., "magic mint") is a member of the Sage family that has been used for divination and shamanism by the Mazatecs. Over the past decade or so, S. divinorum has been increasingly used recreationally. The neoclerodane diterpene salvinorin A is the active component of S. divinorum, and recently, the kappa opioid receptor (KOR) has been identified, in vitro and in vivo, as its molecular target. The discovery of KOR as the molecular target of salvinorin A has opened up many opportunities for drug discovery and drug development for a number of psychiatric and non-psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035666     DOI: 10.1124/mi.6.5.7

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  30 in total

1.  Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via extracellular signal-regulated kinase/mitogen-activated protein kinase in piglets.

Authors:  Diansan Su; John Riley; William M Armstead; Renyu Liu
Journal:  Anesth Analg       Date:  2011-11-10       Impact factor: 5.108

2.  Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo.

Authors:  Gabriella Aviello; Francesca Borrelli; Francesca Guida; Barbara Romano; Kevin Lewellyn; Maria De Chiaro; Livio Luongo; Jordan K Zjawiony; Sabatino Maione; Angelo A Izzo; Raffaele Capasso
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

3.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

4.  Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.

Authors:  Feng Yan; Ruslan V Bikbulatov; Viorel Mocanu; Nedyalka Dicheva; Carol E Parker; William C Wetsel; Philip D Mosier; Richard B Westkaemper; John A Allen; Jordan K Zjawiony; Bryan L Roth
Journal:  Biochemistry       Date:  2009-07-28       Impact factor: 3.162

Review 5.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

6.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

Review 7.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

8.  Biosynthesis of salvinorin A proceeds via the deoxyxylulose phosphate pathway.

Authors:  Lukasz Kutrzeba; Franck E Dayan; J'Lynn Howell; Ju Feng; José-Luis Giner; Jordan K Zjawiony
Journal:  Phytochemistry       Date:  2007-06-14       Impact factor: 4.072

Review 9.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria.

Authors:  Michael R Bruchas; Benjamin B Land; Megumi Aita; Mei Xu; Sabiha K Barot; Shuang Li; Charles Chavkin
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.